Applied Therapeutics Inc. APLT
We take great care to ensure that the data presented and summarized in this overview for Applied Therapeutics Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding APLT
View all-
Janus Henderson Group PLC London, X010.5MShares$11.6 Million0.05% of portfolio
-
Morgan Stanley New York, NY9.9MShares$10.9 Million0.01% of portfolio
-
Vr Adviser, LLC New York, NY9.83MShares$10.8 Million8.65% of portfolio
-
Perceptive Advisors LLC New York, NY8.01MShares$8.81 Million1.78% of portfolio
-
Franklin Resources Inc San Mateo, CA6.8MShares$7.48 Million0.02% of portfolio
-
Black Rock Inc. New York, NY6.57MShares$7.23 Million0.0% of portfolio
-
Propel Bio Management, LLC Los Angeles, CA6.57MShares$7.22 Million32.38% of portfolio
-
Knoll Capital Management, LLC Miami, FL5.57MShares$6.13 Million23.38% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.24MShares$5.77 Million0.0% of portfolio
-
Deutsche Bank Ag\ Frankfurt Am Main, 2M4.44MShares$4.88 Million0.02% of portfolio
Latest Institutional Activity in APLT
Top Purchases
Top Sells
About APLT
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Insider Transactions at APLT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 19
2024
|
Leslie D. Funtleyder |
BUY
Grant, award, or other acquisition
|
Direct |
150,000
+25.96%
|
-
|
|
Dec 19
2024
|
John Johnson Executive Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
500,000
+50.0%
|
-
|
|
Aug 22
2024
|
Leslie D. Funtleyder |
SELL
Open market or private sale
|
Direct |
13,530
-4.64%
|
$67,650
$5.83 P/Share
|
|
Aug 22
2024
|
Riccardo Perfetti Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
22,681
-2.25%
|
$113,405
$5.83 P/Share
|
|
Aug 14
2024
|
Shoshana Shendelman President and CEO |
SELL
Open market or private sale
|
Direct |
119,591
-2.49%
|
$597,955
$5.93 P/Share
|
|
Aug 13
2024
|
Shoshana Shendelman President and CEO |
SELL
Open market or private sale
|
Direct |
357,423
-6.92%
|
$2,144,538
$6.18 P/Share
|
|
Aug 12
2024
|
Shoshana Shendelman President and CEO |
SELL
Open market or private sale
|
Direct |
300,000
-5.49%
|
$1,500,000
$5.98 P/Share
|
|
Aug 05
2024
|
Shoshana Shendelman President and CEO |
BUY
Bona fide gift
|
Indirect |
747,886
+50.0%
|
-
|
|
Aug 05
2024
|
Shoshana Shendelman President and CEO |
SELL
Bona fide gift
|
Indirect |
747,886
-100.0%
|
-
|
|
Jun 06
2024
|
Shoshana Shendelman President and CEO |
SELL
Open market or private sale
|
Direct |
61,795
-1.62%
|
$247,180
$4.32 P/Share
|
|
Jun 06
2024
|
Leslie D. Funtleyder |
SELL
Open market or private sale
|
Direct |
16,980
-5.51%
|
$67,920
$4.32 P/Share
|
|
Jun 06
2024
|
Riccardo Perfetti Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
22,003
-2.13%
|
$88,012
$4.32 P/Share
|
|
Jun 06
2024
|
Stacy J. Kanter |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+29.41%
|
-
|
|
Jun 06
2024
|
Joel S Marcus |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+8.28%
|
-
|
|
Jun 06
2024
|
Jay S Skyler |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+40.91%
|
-
|
|
Jun 06
2024
|
Teena Lerner |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+29.92%
|
-
|
|
Jun 05
2024
|
Alexandria Real Estate Equities, Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
150,000
-2.5%
|
$600,000
$4.24 P/Share
|
|
Jun 04
2024
|
Alexandria Real Estate Equities, Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
150,000
-2.44%
|
$600,000
$4.21 P/Share
|
|
Apr 12
2024
|
Corwin Dale Hooks Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
300,000
+50.0%
|
-
|
|
Mar 14
2024
|
Shoshana Shendelman President and CEO |
SELL
Open market or private sale
|
Direct |
318,573
-7.7%
|
$1,592,865
$5.39 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 1.43M shares |
|---|---|
| Bona fide gift | 748K shares |
| Open market or private sale | 1.72M shares |
|---|---|
| Bona fide gift | 748K shares |